PepVault
/ database / Growth Hormone Releasing Hormone Analog

Tesamorelin

Also: Egrifta

The visceral-fat peptide — FDA-approved for HIV-associated lipodystrophy.

Evidence
established
Legal status
rx only
Half-life
~26 min (peptide), but downstream GH effect lasts hours
Routes
subq
View on Limitless LifeAdd to compare
What it is

Tesamorelin is one of the only GHRH analogs with robust human clinical data. It is FDA-approved for reducing visceral adipose tissue in patients with HIV-associated lipodystrophy, and is studied for cognitive and metabolic benefits in aging populations.

Mechanism

A stabilized GHRH analog. Selectively reduces visceral adipose tissue in studied populations.

Outcomes it's matched to
Safety

Generally well tolerated; injection-site reactions most common.

  • Active malignancy
  • Pregnancy
  • Hypopituitarism
Legal context

Prescription medication in the US (Egrifta).

1:1 GUIDANCE

Have questions about this peptide?

Get free 1:1 guidance from a peptide professional before you start. They'll help you think through dosing, stacking, and whether this fits your goals.

REQUEST A CALL →
PepVault

An outcome-driven reference for modern peptides. Educational only — not medical advice, not a sales platform, not affiliated with any clinic.

Disclaimer: PepVault is an educational resource. Nothing on this site is medical advice. Many peptides discussed are research compounds and are not approved by the FDA or equivalent agencies. Always consult a qualified clinician before starting any protocol.

© 2026 PepVault